StreetInsider.com News Articles

Qiagen NV (QGEN) PT Raised to $48 at Jefferies

Thu, 06 Aug 2026 15:23:08 -0400

Jefferies analyst Tycho Peterson raised the price target on Qiagen NV (NYSE: QGEN) to $48.00 (from $46.00) while maintaining a Buy rating.

Qiagen (QGEN) spreader of 1500 contracts of August 45 and 3K contracts of September 45 calls

Thu, 06 Aug 2026 14:18:54 -0400

Qiagen (NYSE: QGEN) 30-day call option implied volatility is 47; compared to its 52-week range of 18 to 59 with a focus on a spreader of 1500 contracts of August 45 and 3K contracts of September 45 calls.

Qiagen (QGEN) Tops Q2 EPS by 2c

Wed, 05 Aug 2026 16:43:55 -0400

Qiagen (NYSE: QGEN) reported Q2 EPS of $0.62, $0.02 better than the analyst estimate of $0.60. Revenue for the quarter came in at $535 million versus the consensus estimate of $530.77 million.

For earnings history and earnings-related data on Qiagen (QGEN) click here.

Qiagen tops Q2 outlook with flat sales, reaffirms 2026 guidance

Wed, 05 Aug 2026 16:05:55 -0400

QIAGEN N.V. (NYSE: QGEN) reported net sales of $535 million for its second quarter of fiscal 2026, unchanged from the same period a year earlier on both a reported and constant exchange rate (CER) basis, according to a company statement. The result exceeded the company's prior outlook for an approximately 2% CER decline.

The company's growth pillars collectively delivered approximately 5% CER growth during the quarter. Sample technologies led the gains, with consumables growing at a high single-digit CER rate and instruments at a mid-single-digit CER rate. QIAcuity and QIAGEN Digital Insights also contributed to growth. QuantiFERON sales rose 1% CER,

Qiagen tops Q2 outlook with flat sales, reaffirms 2026 guidance

Wed, 05 Aug 2026 16:05:55 -0400

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:
- Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline
- Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand
- Adjusted operating income margin of 29.4%, maintaining a high level of profitability
- Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER
H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

Wed, 05 Aug 2026 16:05:00 -0400

Q2 2026 results:

Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline

Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand

Adjusted operating income margin of 29.4%, maintaining a high level of profitability

Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER

H1 2026 operating cash of $301 million remains at a strong level

Citi Assumes Qiagen NV (QGEN) at Neutral

Thu, 30 Jul 2026 10:03:20 -0400

Citi analyst Brendan Digan assumes coverage on Qiagen NV (NYSE: QGEN) with a Neutral rating and a price target of $38.00.

For an analyst ratings summary and ratings history on Qiagen NV click here. For more ratings news on Qiagen NV click here.

Shares of Qiagen NV closed at $41.81 yesterday.

Qiagen (QGEN) spreader of 10K contracts of August 40 and 20K contracts of August 45 calls

Mon, 27 Jul 2026 14:46:21 -0400

Qiagen (NYSE: QGEN) 30-day call option implied volatility is 54; compared to its 52-week range of 18 to 59 with a focus on a spreader of 10K contracts of August 40 and 20K contracts of August 45 calls.

QIAGEN touts Cyclospora detection tools amid U.S. outbreak

Wed, 15 Jul 2026 16:05:55 -0400

QIAGEN N.V. (NYSE: QGEN) highlighted its molecular testing products for detecting Cyclospora cayetanensis as U.S. health authorities report more than 1,600 confirmed cases of cyclosporiasis since May 2026, along with approximately 7,000 potential cases, according to a company press release.
The foodborne parasite, which can cause prolonged diarrhea and other gastrointestinal symptoms, is not detectable through routine stool culture and requires specialized diagnostic methods.
The company's FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 includes Cyclospora cayetanensis as one of 16 targets covering bacterial, viral, and parasitic pathogens. The test delivers results in approximately one hour from a single patient sample.
For research use only, QIAGEN

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

Wed, 15 Jul 2026 16:05:00 -0400

More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwide

QIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour as part of a 16-target gastrointestinal pathogens menu

QIAGEN also offers QIAcuity digital PCR and QIAseq next-generation sequencing tools for research and public health investigations

GERMANTOWN, Md., & VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today highlighted its portfolio of molecular testing solutions supporting the public health response to the growing number of cyclosporiasis

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

Wed, 15 Jul 2026 08:48:00 -0400

VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2026.
Press release date / time: Wednesday, August 5 shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by